Phase 2 Kidney Cancer Trial, Recruiting NCT06948552 Sponsor: Henry Ford Health System Condition: Kidney Cancer
Back to Kidney Cancer

Phase 2 Kidney Cancer Trial, Recruiting

NCT06948552
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are scheduled to have a ureteroscopy procedure (a procedure where a thin camera is used to look inside the urinary tract) to investigate or treat a known or suspected tumor in the upper urinary tract
  • People who are able to give their informed consent to participate
  • People who are able to follow the requirements of the study

Who may not be able to join:

  • People who have a condition called porphyria, or who have had a bad reaction to a group of substances called porphyrins
  • Women who are pregnant or breastfeeding
  • People whose liver function blood test results have been more than twice the normal level within the 30 days before their surgery
  • People who have taken part in another research trial within the past 30 days
  • People who have a known allergy or medical reason not to take a substance called 5-ALA or any of its ingredients

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Henry Ford Health System
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Detection of tumor fluorescence using 5-ALA under blue light

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov